علاج نقص هرمون النمو لدى الأطفال

References

DOI: 10.1159/000452150

• The primary objectives of GH treatment for patients with GHD are acceleration of growth velocity to promote normalization of growth and stature during childhood and attainment of normal AH appropriate for the child's genetic potential.
• We recommend the use of weight-based or body surface area (BSA)-based GH dosing in children with GHD.
• We recommend an initial GH dose of 0.16–0.24 mg/kg/week (22–35 μg/kg/day) with individualization of subsequent dosing.
• Some patients may require higher doses.
• We suggest that the GH dose be lowered if serum IGF-I levels rise above the laboratory-defined normal range for the age or pubertal stage of the patient.
• We recommend that GH treatment at pediatric doses not continue beyond attainment of a growth velocity below 2–2.5 cm/year.